eprosartan
Trade name: teveten
Approved
Dec 22, 1997
Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure. Eprosartan is indicated for the management of hypertension alone or in combination with other classes of antihypertensive agents. Also used as a first-line agent in the treatment of diabetic nephropathy, as well as a second-line agent in the treatment of congestive heart failure (only in those intolerant of ACE inhibitors). — NCATS
Clinical trial activity
8 trials · 10 clinical orgs · 4 marketing orgs
Earliest trial started Oct 1, 2004 (NCT00160160)
Timeline
1990s
- Dec 22, 1997
Earliest FDA Approval
- Dec 22, 1997
AbbVie — NDA Secondary Org
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
- Nov 16, 2011
Mylan — Marketing Organization
- Nov 16, 2011
PHARMOBEDIENT — Marketing Organization
- Jan 1, 2012
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Type-1 angiotensin II receptorANTAGONIST
AGTR1 antagonist
Combination products
teveten hct
with hydrochlorothiazide
Approval history
- approvedDec 22, 1997
Chemistry & pharmacology
SMILES
CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1- Mol. weight
- 424.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL813 ↗
- WikipediaEprosartan ↗
- NCATS2KH13Z0S0Y ↗
- ChEMBLCHEMBL1200987 ↗
Also known as
- 2-thiophenepropanoic acid, alpha-((2-butyl-1-((4- carboxyphenyl)methyl)-lh-imidazol-5-yl)methylene)-, (e)-
- (e)-2-butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid
- (e)-2-butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid
- (e)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1h-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid
- (e)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1h-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid
- (e)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1h-imidazole-5-yl]methylene}-2-thiopheneproprionic acid
- (e)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1h-imidazole-5-yl]methylene}-2-thiopheneproprionic acid
- eposartan
- eprosartan
- eprosartan
- eprosartan
- eprosartan
- eprosartan
- eprosartan
- eprosartan
- eprosartan
- eprosartan
- eprosartan
- éprosartan
- éprosartan
- eprosartan mesilate
- eprosartan mesylate
- eprosartan mesylate
- eprosartan mesylate
- eprosartan mesylate
- eprosartan mesylate
- eprosartanum
- eprosartanum
- sk-108566
- sk-108566
- sk&f 108566
- sk&f-108566
- sk&f-108566
- skf-108566
- sk&f-108566j
- sk&f-108566j
- sk&f-108566-j
- sk&f-108566-j
- teveten
- teveten
- teveten
- teveten
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02817360 | Phase 4 | Feb 1, 2016 | Medical University of Vienna, University of Vienna |
| NCT01631227 | Phase 3 | Jun 1, 2012 | Abbott, IQVIA, Synexus |
| NCT01502904 | Phase 4 | Jul 1, 2010 | Yonsei University |
| NCT01087749 | Phase 1 | Mar 1, 2010 | University of California, San Francisco |
| NCT04954560 | N/A | Jan 1, 2008 | Medical University of Lodz |
| NCT00438945 | Phase 4 | Jan 1, 2007 | Aarhus University |
| NCT00409903 | Phase 4 | Nov 1, 2006 | Aarhus University |
| NCT00160160 | N/A | Oct 1, 2004 | Solvay |
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aarhus University | Academic/Hospital | 2 | 2 | 1 | 2006 |
| Abbott | For profit | 1 | 1 | 1 | 2012 |
| IQVIA | For profit | 1 | 0 | 1 | 2012 |
| Medical University of Lodz | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Medical University of Vienna | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Solvay | For profit | 1 | 1 | 1 | 2004 |
| Synexus | For profit | 1 | 0 | 1 | 2012 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Vienna | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2010 |
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AbbVie | For profit | NDA2 | Dec 22, 1997 |
| Mylan | For profit | MKTG | Nov 16, 2011 |
| PHARMOBEDIENT | For profit | MKTG | Nov 16, 2011 |
| SmithKline Beecham | For profit | NDA | — |